Selegiline Hydrochloride | CAS#14611-52-0 | CAS#14611-51-9 | MAO-B Selective Inhibitor

MedKoo Cat#: 318688 | Name: Selegiline Hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Selegiline hydrochloride is a selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability.

Chemical Structure

Selegiline Hydrochloride

CAS#14611-52-0 (HCl)

Theoretical Analysis

MedKoo Cat#: 318688

Name: Selegiline Hydrochloride

CAS#: 14611-52-0 (HCl)

Chemical Formula: C13H18ClN

Exact Mass: 0.0000

Molecular Weight: 223.74

Elemental Analysis: C, 69.79; H, 8.11; Cl, 15.85; N, 6.26

Price and Availability

Size	Price	Availability
25mg	USD 135.00	Ready to ship
50mg	USD 210.00	Ready to ship
100mg	USD 350.00	Ready to ship
200mg	USD 550.00	Ready to ship
500mg	USD 1,250.00	Ready to ship
1g	USD 2,150.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

14611-52-0 (HCl) 14611-51-9 (free base) 4528-51-2 (racemate)

Synonym

Selegiline Hydrochloride; Eldepryl; Selegiline Hcl; Zelapar; L-Deprenyl hydrochloride; Deprenalin; Deprenyl; E 250, E250, E-250

IUPAC/Chemical Name

(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;hydrochloride

InChi Key

IYETZZCWLLUHIJ-UTONKHPSSA-N

InChi Code

InChI=1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1

SMILES Code

CC(CC1=CC=CC=C1)N(C)CC#C.Cl

Appearance

White to off-white crystalline powder.

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C22M12C05

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Selegiline hydrochloride is a selective, irreversible inhibitor of Type B monoamine oxidase.

In vitro activity:

Results indicate that stimulation with LPS significantly increased the permeability of bEnd.3 cells and reduced the expression of JAM-A, both of which were rescued by treatment with selegiline. Additionally, selegiline prevented the activation of the NF-κB/MLCK/p-MLC signaling pathway in LPS-challenged bEnd.3 cells. These results indicate that selegiline exerted a protective effect on BBB dysfunction, which might be attributed to the inhibition of the NF-κB/MLCK/p-MLC signaling pathway. Reference: Neurotox Res. 2022 Feb;40(1):267-275. https://pubmed.ncbi.nlm.nih.gov/34981455/

In vivo activity:

Daily pretreatment with 0.1 mg kg-1 (i.p.) selegiline for two weeks, however, dramatically increased extracellular concentration of DA (dopamine) to about seven times that of control animals treated with levodopa/carbidopa alone in marmosets. Such an increase in extracellular concentrations of DA could not be observed in a similar study with Wistar rats. This study showed that chronic administration of a small dose of selegiline caused a marked increase in extracellular DA concentration in the striatum of primates, but not in the rodents. Reference: Brain Res. 1999 Jan 2;815(1):44-50. https://pubmed.ncbi.nlm.nih.gov/9974121/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	134.08
	DMSO	30.0	134.08
	Ethanol	30.0	134.08
	PBS (pH 7.2)	10.0	44.69

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 223.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Pu Y, Qian F, Guo J, Sha Y, Qian Y. Selegiline Protects Against Lipopolysaccharide (LPS)-Induced Impairment of the Blood-Brain Barrier Through Regulating the NF-κB/MLCK/p-MLC Signaling Pathway. Neurotox Res. 2022 Feb;40(1):267-275. doi: 10.1007/s12640-021-00448-5. Epub 2022 Jan 4. PMID: 34981455. 2. Cui Y, Liu KW, Liang Y, Ip MS, Mak JC. Inhibition of monoamine oxidase-B by selegiline reduces cigarette smoke-induced oxidative stress and inflammation in airway epithelial cells. Toxicol Lett. 2017 Feb 15;268:44-50. doi: 10.1016/j.toxlet.2017.01.005. Epub 2017 Jan 17. PMID: 28108387. 3. Abdanipour A, Mirzaei M, Anarkooli IJ, Mohammadi P. Effect of selegiline as a monomine oxidase B inhibitor on the expression of neurotrophin mRNA levels in a contusion rat model of spinal cord injury. Neurol Res. 2022 Dec 1:1-7. doi: 10.1080/01616412.2022.2129761. Epub ahead of print. PMID: 36453689. 4. Kaseda S, Nomoto M, Iwata S. Effect of selegiline on dopamine concentration in the striatum of a primate. Brain Res. 1999 Jan 2;815(1):44-50. doi: 10.1016/s0006-8993(98)01089-0. PMID: 9974121.

In vitro protocol:

In vivo protocol:

1. Abdanipour A, Mirzaei M, Anarkooli IJ, Mohammadi P. Effect of selegiline as a monomine oxidase B inhibitor on the expression of neurotrophin mRNA levels in a contusion rat model of spinal cord injury. Neurol Res. 2022 Dec 1:1-7. doi: 10.1080/01616412.2022.2129761. Epub ahead of print. PMID: 36453689. 2. Kaseda S, Nomoto M, Iwata S. Effect of selegiline on dopamine concentration in the striatum of a primate. Brain Res. 1999 Jan 2;815(1):44-50. doi: 10.1016/s0006-8993(98)01089-0. PMID: 9974121.

1: Lees AJ. Selegiline hydrochloride and cognition. Acta Neurol Scand Suppl. 1991;136:91-4. doi: 10.1111/j.1600-0404.1991.tb05027.x. PMID: 1801544. 2: Khot KB, D S S, Gopan G, Deshpande N S, Shastry P, Bandiwadekar A, Jose J. Enhancing selegiline hydrochloride efficacy: Box Behnken-optimized liposomal delivery via intranasal route for Parkinson's disease intervention. J Liposome Res. 2024 Apr 9:1-18. doi: 10.1080/08982104.2024.2336549. Epub ahead of print. PMID: 38591935. 3: Salatin S, Asadi R, Jelvehgari M. Development and characterization of sublingual films for enhanced bioavailability of selegiline hydrochloride. Ther Deliv. 2021 Feb;12(2):159-174. doi: 10.4155/tde-2020-0118. Epub 2021 Feb 9. PMID: 33557601. 4: Lees AJ. The on-off phenomenon. J Neurol Neurosurg Psychiatry. 1989 Jun;Suppl(Suppl):29-37. doi: 10.1136/jnnp.52.suppl.29. PMID: 2666577; PMCID: PMC1033307. 5: George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003 Jan 15;53(2):136-43. doi: 10.1016/s0006-3223(02)01454-3. PMID: 12547469. 6: Kamada T, Chow T, Hiroi T, Imaoka S, Morimoto K, Ohde H, Funae Y. Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet. 2002;17(3):199-206. doi: 10.2133/dmpk.17.199. PMID: 15618670. 7: Müller FO, Schall R, Hundt HK, Joubert A, Middle MV, Muir AR, Duursema L, Groenewoud G, Swart KJ. Bioavailability of two selegiline hydrochloride tablet products. Arzneimittelforschung. 1996 Nov;46(11):1037-40. PMID: 8955861. 8: Mishra N, Sharma S, Deshmukh R, Kumar A, Sharma R. Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease. Cent Nerv Syst Agents Med Chem. 2019;19(1):46-56. doi: 10.2174/1871524919666181126124846. PMID: 30474538. 9: Mills D, Ledger R. The effects of oral selegiline hydrochloride on learning and training in the dog: a psychobiological interpretation. Prog Neuropsychopharmacol Biol Psychiatry. 2001 Nov;25(8):1597-613. doi: 10.1016/s0278-5846(01)00205-6. PMID: 11642657. 10: Singh D, Rashid M, Hallan SS, Mehra NK, Prakash A, Mishra N. Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression. Artif Cells Nanomed Biotechnol. 2016 May;44(3):865-77. doi: 10.3109/21691401.2014.998824. Epub 2015 Jun 4. PMID: 26042481. 11: Salatin S, Alami-Milani M, Daneshgar R, Jelvehgari M. Box-Behnken experimental design for preparation and optimization of the intranasal gels of selegiline hydrochloride. Drug Dev Ind Pharm. 2018 Oct;44(10):1613-1621. doi: 10.1080/03639045.2018.1483387. Epub 2018 Aug 20. PMID: 29932793. 12: Sridhar V, Wairkar S, Gaud R, Bajaj A, Meshram P. Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease. J Drug Target. 2018 Feb;26(2):150-161. doi: 10.1080/1061186X.2017.1350858. Epub 2017 Jul 18. PMID: 28682134. 13: Barrett JS, Szego P, Rohatagi S, Morales RJ, De Witt KE, Rajewski G, Ireland J. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharm Res. 1996 Oct;13(10):1535-40. doi: 10.1023/a:1016035730754. PMID: 8899847. 14: Rukmangathen R, Yallamalli IM, Yalavarthi PR. Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease. Curr Drug Discov Technol. 2019;16(4):417-425. doi: 10.2174/1570163815666180418144019. PMID: 29669501. 15: Wasnik MN, Godse RD, Nair HA. Development and evaluation of buccoadhesive tablet for selegiline hydrochloride based on thiolated polycarbophil. Drug Dev Ind Pharm. 2014 May;40(5):632-8. doi: 10.3109/03639045.2014.884124. Epub 2014 Feb 12. PMID: 24517570. 16: Kivistö KT, Wang JS, Backman JT, Nyman L, Taavitsainen P, Anttila M, Neuvonen PJ. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol. 2001 Apr;57(1):37-42. doi: 10.1007/s002280100278. PMID: 11372588. 17: Iijima M, Mitoma H, Uchiyama S, Kitagawa K. Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson's Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance. Front Neurol. 2017 Oct 24;8:542. doi: 10.3389/fneur.2017.00542. PMID: 29114238; PMCID: PMC5660685. 18: Scheinin H, Anttila M, Dahl ML, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L. CYP2D6 polymorphism is not crucial for the disposition of selegiline. Clin Pharmacol Ther. 1998 Oct;64(4):402-11. doi: 10.1016/S0009-9236(98)90071-6. PMID: 9797797. 19: da Silva Mesquita B, do Egito Vasconcelos BC, Amorim Gomes AC, de Souza Andrade ES. Effectiveness of Selegiline Hydrochlorate in Treating Neurosensory Disorders of the Lower Alveolar Nerve Resulting From Mandibular Sagittal Osteotomy: Preliminary Study. Ann Plast Surg. 2020 Dec;85(6):645-649. doi: 10.1097/SAP.0000000000002607. PMID: 33165116. 20: Dixit SN, Behari M, Ahuja GK. Effect of selegiline on cognitive functions in Parkinson's disease. J Assoc Physicians India. 1999 Aug;47(8):784-6. PMID: 10778622.

View History

Description:

Chemical Structure

Theoretical Analysis

Price and Availability

Preparing Stock Solutions

View History

Selank

AS-1410

Cordyheptapeptide A

COR1-25

Error message: